Laura Marlow

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Radical Prostatectomy

Positron Emission Tomography

Small Cell Lung Cancer

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics 23 (6) (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Molecular cancer therapeutics 23 (6) (2024)
Adam M Kase, Justyna Joanna Gleba, James L Miller, Erin Miller, Joachim L Petit, Michael T Barrett, Yumei Zhou, Ephraim E Parent, Hancheng Cai, Joshua A Knight, Jacob J Orme, Jordan P Reynolds, William F Durham, Thomas M Metz, Nathalie Meurice, Brandy Edenfield, Aylin A Demirer, Ahmet Bilgili, Peyton G Hickman, Matthew L Pawlush, Laura Marlow, Daniel P Wickland, Winston Tan, John A Copland Iii
Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer. Molecular cancer therapeutics (2024)